EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Novel biomarkers distinguish heart failure with preserved vs reduced ejection fraction

Camilla Hage iD, Annika Mang, Jean-Claude Daubert, Erwan Donal iD, Peder L Myhre, Cecilia Linde iD, Lars H Lund

ESC Heart Failure · 05.05.2026 · 13 (3)

DOI: 10.1093/eschf/xvaf011 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, online erschienen am 08.01.2026. Verfasst von Camilla Hage und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Ventricular Function, Left. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fédération Française de Cardiologie/Société Française de Cardiologie, France, Medtronic Bakken Research Center, Maastricht, The Netherlands.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Heart failure (HF) with preserved (HFpEF) and reduced (HFrEF) ejection fraction may be driven by different pathophysiologies. We explored novel biomarkers, associations with clinical characteristics, discrimination between LVEF categories and associations with outcomes. Methods and results In HFpEF(n = 76) and HFrEF(n = 36), 19 plasma biomarkers were measured including seven novel research assays for ANGPT2, BMP10, DKK3, FABP3, FGF23, IGFBP7, and MYBPC3. Heart failure with preserved ejection fraction patients were older (73 vs 63 years), more often female (50% vs 14%). All seven novel biomarkers except FABP3 tended to be higher in HFrEF vs HFpEF and associated with worse NYHA class and lower eGFR in both LVEF categories. MYBPC3 and FGF23 (higher in HFrEF) discriminated best between LVEF categories (AUC 85.8 and 80.0 respectively). In HFpEF, higher ANGPT2 was associated with worse right (TAPSE: β = −1.03;P = .04) and left ventricular function (LV-GLS; β = 1.29;P = .03) and left atrial strain (LA-GLS: β = 5.03;P < .001) whereas higher IGFBP7 and MYBPC3 with diastolic dysfunction (E/eʹ: β = 4.09;P = .02 and β = 1.36;P = .01 respectively). All biomarkers except DKK3 were positively associated with the outcome (HFpEF:all-cause death, HF hospitalization;HFrEF: all-cause death, LVAD or heart transplantation). Specifically ANGPT2 [HR 1.45(95% CI 1.00–2.13)] more strongly in HFpEF and IGFBP7 [2.51(0.95–6.64)] more strongly in HFrEFand MYBPC3 [1.62(0.99–2.64)].

Conclusion

Among seven novel biomarker assays, higher MYBPC3 (reflecting muscle injury and myopathy) and FGF23 (endothelial dysfunction, oxidative stress) distinguished HFrEF from HFpEF. Higher MYBPC3 was most prognostic in HFrEF while higher ANGPT2 and IGFBP7 (endothelial dysfunction and oxidative stress) in HFpEF. These hypothesis-generating findings support primary cardiomyocyte injury as a driver of HFrEF and systemic inflammation and oxidative stress as a driver of HFpEF. Clinical Trial Registration ClinicalTrials.gov NCT00774709

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeVentricular Function, LeftAgedFemaleHumansMaleMiddle AgedBiomarkersFibroblast Growth Factor-23Prognosis

Stichwörter der Autor:innen

HFpEFHFrEFbiomarkeroxidative stresspathophysiologyphenotype

Substanzen

BiomarkersFGF23 protein, humanFibroblast Growth Factor-23

Autor:innen und Institutionen

  • Cardiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Department of Cardiology, Karolinska University Hospital, Stockholm SE-171 64, Sweden.
  • Roche Diagnostics GmbH, Penzberg, Germany.
  • Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
  • K.G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

ORCID-Profile: Camilla Hage, Erwan Donal, Cecilia Linde

Förderung

  • Fédération Française de Cardiologie/Société Française de Cardiologie, France
  • Medtronic Bakken Research Center, Maastricht, The Netherlands

Zitieren

APA

Hage, C., Mang, A., Daubert, J. C., Donal, E., Myhre, P. L., Linde, C., & Lund, L. H. (2026). Novel biomarkers distinguish heart failure with preserved vs reduced ejection fraction. ESC Heart Failure, 13(3). https://doi.org/10.1093/eschf/xvaf011

Vancouver

Hage C, Mang A, Daubert JC, Donal E, Myhre PL, Linde C, et al. Novel biomarkers distinguish heart failure with preserved vs reduced ejection fraction. ESC Heart Failure. 2026;13(3). doi:10.1093/eschf/xvaf011

BibTeX
@article{Hage2026,
  author = {Hage, Camilla and Mang, Annika and Daubert, Jean-Claude and Donal, Erwan and Myhre, Peder L and Linde, Cecilia and Lund, Lars H},
  title = {Novel biomarkers distinguish heart failure with preserved vs reduced ejection fraction},
  journal = {ESC Heart Failure},
  year = {2026},
  volume = {13},
  number = {3},
  doi = {10.1093/eschf/xvaf011}
}
Kostenlos starten →